Table 5 Time to metastasis/recurrence from diagnosis (N = 438 patients)*
Univariable | Multivariable | ||||
|---|---|---|---|---|---|
Characteristics | Median time (months) (95% CI) | P value | Wald | Hazard ratio (CI 95%) | P value |
Type of cancer | |||||
Gastrointestinal (n = 123) vs not | 0.67 (0–1.9) vs 14.1 (8.3–19.8) | < 0.001 | – | – | – |
Brain (n = 109) vs not | 42.8 (19.0–66.7) vs 2.5 (0.49–4.4) | < 0.001 |
|
|
|
Lung (n = 102) vs not | 0.6 (0–1.3) vs 14.0 (9.5–18.6) | < 0.001 | – | – | – |
Breast (n = 51) vs not | 30.4 (14.3–46.4) vs 7.0 (3.8–10.2) | 0.001 | 40.03 | 0.33 (0.23–0.47) | < 0.001 |
Genitourinary (n = 18) vs not | 0 (−) vs 10.1 (6.8–13.4) | 0.020 | – | – | – |
Head and neck (n = 10) vs not | 0 (−) vs 9.8 (6.2–13.4) | 0.015 | – | – | – |
Genetic alteration type | |||||
MET (n = 31) vs not | 1.0 (−) vs 10.4 (6.9–14.0) | 0.003 | 4.05 | 1.47 (1.01–2.13) | 0.044 |
TP53 (n = 149) vs not | 4.1 (0.5–7.7) vs 12.7 (6.1–19.3) | 0.001 | – | – | – |
EGFR (n = 53) vs not | 3.6 (0–8.2) vs 11.4 (7.9–14.8) | 0.003 | – | – | – |
ARID1A (n = 19) vs not | 3.6 (0–10.1) vs 10.0 (6.3–13.7) | 0.013 | – | – | – |
KRAS (n = 50) vs not | 0 (−) vs 11.4 (8.3–13.7) | < 0.001 | – | – | – |
SMAD4 (n = 12) vs not | 0 (−) vs 10.1 (6.7–13.4) | 0.040 | – | – | – |
MYC (n = 20) vs not | 0.2 (0–0.75) vs 10.4 (7.0–13.9) | < 0.001 | – | – | – |
Metastatic sites | |||||
Adrenal (n = 29) vs not | 0 (−--) vs 11.3 (8.0–14.6) | 0.002 | – | – | – |
Bone (n = 102) vs not | 1.5 (0–6.7) vs 11.4 (8.2–14.5) | 0.049 | – | – | – |
Liver (n = 111) vs not | 0.9 (0–2.6) vs 132.3 (9.7–16.9) | < 0.001 | 10.04 | 1.49 (1.16–1.92) | 0.022 |
Lymph node (n = 139) vs not | 0.3 (−) vs 20.1 (14.3–25.9) | < 0.001 | 13.41 | 1.54 (1.22–1.92) | < 0.001 |
Peritoneal (n = 49) vs not | 0 (−) vs 11.3 (8.1–14.5) | < 0.001 | – | – | – |
Brain (n = 63) vs not | 3.6 (0–7.8) vs 10.4 (7.0–13.9) | 0.045 | – | – | – |
Lung (n = 90) vs not | 1.2 (0–8.0) vs 11.3 (7.7–15.0) | 0.003 | – | – | – |